Author: Cindy Birck

  • The Euro-PAD initiative holds a scientific symposium in Amsterdam

    The Euro-PAD initiative holds a scientific symposium in Amsterdam

    On 16 and 17 May, the Euro-PAD initiative held a scientific symposium in Amsterdam, aimed to discuss the latest developments in neuroimaging and biomarkers for Alzheimer’s disease. This year, the event began with two imaging workshops on the advancements in Positron Emission Tomography (PET) and advanced Magnetic Resonance Imaging (MRI) quantification.

    The first afternoon of the symposium officially commenced with a warm welcome from Frederik Barkhof and Lyduine Collij, establishing a collaborative atmosphere for the event. Over 70 participants attended the meeting in person, highlighting the strong interest and commitment within the scientific community. The opening session featured an overview of the Euro-PAD initiative, highlighting the substantial progress made over the past year. The symposium’s agenda was packed with insightful scientific sessions covering key topics such as the use of Amyloid-PET in the clinical routine and trials, advancements in disease modelling and MRI-PET analysis. Additionally, on the second day, sessions covered topics on imaging/genetics and developments in fluid biomarkers.

    Euro-PAD continues the pioneering efforts of the AMYPAD pan-European collaborative framework, integrating several major cohorts including EPAD, AMYPAD, ALFA+, Prevent-AD and Microbiota. This year, new cohorts were introduced, including the T-POT study, Insight-preAD, SCIENCe and REALAD, reflecting the consortium’s expanding scope. The two-day event was marked by lively discussions where delegates had the opportunity to present their latest results, share insights and explore potential collaborations.

    by

    in

    On 16 and 17 May, the Euro-PAD initiative held a scientific symposium in Amsterdam, aimed to discuss the latest developments in neuroimaging and biomarkers for Alzheimer’s disease. This year, the event began with two imaging workshops on the advancements in Positron Emission Tomography (PET) and advanced Magnetic Resonance Imaging (MRI) quantification. The first afternoon of…

  • Announcing the Enhanced EPND Catalogue

    Announcing the Enhanced EPND Catalogue

    EPND is working to accelerate global progress in neurodegenerative disease diagnostics, treatments, and biomarkers. The EPND Catalogue brings information about data and biosamples from existing research programs together in a scalable and sustainable platform, providing a single point of access for research discovery and collaboration. 

    The next iteration of the EPND Catalogue expands upon a first-of-its-kind, open, accessible database. It provides discoverability and access to more than 75 studies from 17 countries covering 12 disease areas with more than 240,000 participants, including the EPAD Longitudinal Cohort Study.

    Responding to feedback from researchers, cohorts and data scientists, updates to the EPND Catalogue enhance the visibility and discoverability of studies, offering new pathways for collaborative research and sharing of biosamples and data. The EPND Catalogue now offers:  

    • Improved search and filter functions, with a streamlined interface allowing researchers to easily discover and connect with studies of interest.  
    • Additional categories of information and metadata on study design, participants, datasets and bio sample collections, and their use and access conditions. 

    Join the EPND Catalogue community and change the future of neurodegenerative diseases.  

    by

    in

    EPND is working to accelerate global progress in neurodegenerative disease diagnostics, treatments, and biomarkers. The EPND Catalogue brings information about data and biosamples from existing research programs together in a scalable and sustainable platform, providing a single point of access for research discovery and collaboration.  The next iteration of the EPND Catalogue expands upon a…

  • Special Symposium at 33AEC highlights the value of data sharing

    Special Symposium at 33AEC highlights the value of data sharing

    Over the last decade, substantial efforts have been invested in the development of initiatives, resources and infrastructures for data sharing from clinical research studies. Data sharing has the potential to accelerate and advance dementia research, allowing scientists to make new discoveries using existing data from clinical cohorts, trials and registries. In a Special Symposium organised at the 33rd Alzheimer Europe conference in Helsinki, panellists showed how shared data has generated important insights on the causes, risk factors, diagnosis and treatment of dementia, discussing past challenges and future prospects. The concept of data sharing is not a new one: long before the advent of computers, health economists performed secondary analyses on data from government reports, and meteorologists shared information on weather patterns.

    First, Sarah Bauermeister (University of Oxford), provided an overview of the Dementias Platform UK (DPUK) data sharing platform. DPUK gives researchers anywhere in the world access to high-quality, multi-modal data from 63 population and clinical cohort studies. Sarah also explained how analysis of shared data was able to reveal connections between early life adversity and mental health issues in later life, including depression, partner relationship strain, and poorer cognition.

    The next speaker was Francesca Mangialasche (Karolinska Institutet), Executive Director of the World Wide FINGERS global Scientific Coordinating Center. The World Wide FINGERS network comprises research teams from over 60 countries across the globe, and Francesca detailed their efforts to harmonise global data from the FINGERS studies, to generate robust evidence on dementia prevention. The Alzheimer’s Disease Data Initiative is supporting permissioned, secure access to FINGERS study data via the AD Workbench – a data sharing platform that also powers the EPND (European Platform for Neurodegenerative Diseases) hub.

    The third speaker in the special symposium was Sandar Aye (Karolinska Institutet). Sandar brought the health economics perspective, showing how data from the SveDem population registry can inform mortality and cost analyses for new dementia treatments. SveDem is a Swedish registry study that was initiated in May 2007, recruiting patients from memory clinics across Sweden. To date, over 100,00 patients with a dementia diagnosis have been included in the registry, with yearly follow-up.

    Closing the special symposium, Stina Saunders (Linus Health and University of Edinburgh) brought the focus back to the participant perspective. Focusing on the European Prevention of Alzheimer’s Dementia (EPAD) longitudinal cohort study (LCS), Stina highlighted the valuable contributions of over 2,000 research participants from several countries in Europe. Thanks to their efforts, the EPAD-LCS has generated a valuable biobank and a vast, rich dataset, which is available on the AD Workbench.

    by

    in

    Over the last decade, substantial efforts have been invested in the development of initiatives, resources and infrastructures for data sharing from clinical research studies. Data sharing has the potential to accelerate and advance dementia research, allowing scientists to make new discoveries using existing data from clinical cohorts, trials and registries. In a Special Symposium organised…

  • Journal of the International Neuropsychological Society

    Journal of the International Neuropsychological Society

    “Facilitating clinical use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: Normative data and a diagnostic cutoff value”

    Authors: Merel C. Postema, Mark A. Dubbelman, Jürgen Claesen, Craig Ritchie, Merike Verrijp, Leonie Visser, Pieter-Jelle Visser, Marissa D. Zwan, Wiesje M. van der Flier and Sietske A.M. Sikkes

    Abstract:

    Objective:The Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q) is well validated and commonly used to assess difficulties in everyday functioning regarding dementia. To facilitate interpretation and clinical implementation across different European countries, we aim to provide normative data and a diagnostic cutoff for dementia.

    Methods: Cross-sectional data from Dutch Brain Research Registry (N = 1,064; mean (M) age = 62 ± 11 year; 69.5% female), European Medial Information Framework-Alzheimer’s Disease 90 + (N = 63; Mage = 92 ± 2 year; 52.4% female), and European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (N = 247; Mage = 63 ± 7 year; 72.1% female) were used. The generalized additive models for location, scale, and shape framework were used to obtain normative values (Z-scores). The beta distribution was applied, and combinations of age, sex, and educational attainment were modeled. The optimal cutoff for dementia was calculated using area under receiver operating curves (AUC-ROC) and Youden Index, using data from Amsterdam Dementia Cohort (N = 2,511, Mage = 64 ± 8 year, 44.4% female).

    Results: The best normative model accounted for a cubic-like decrease of IADL performance with age that was more pronounced in low compared to medium/high educational attainment. The cutoff for dementia was 1.85 standard deviation below the population mean (AUC = 0.97; 95% CI [0.97–0.98]).

    Conclusion:We provide regression-based norms for A-IADL-Q and a diagnostic cutoff for dementia, which help improve clinical assessment of IADL performance across European countries.

    DOI: https://doi.org/10.1017/S1355617724000031

    Published online: 8 March 2024 in the Journal of the International Neuropsychological Society

    by

    in

    “Facilitating clinical use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: Normative data and a diagnostic cutoff value” Authors: Merel C. Postema, Mark A. Dubbelman, Jürgen Claesen, Craig Ritchie, Merike Verrijp, Leonie Visser, Pieter-Jelle Visser, Marissa D. Zwan, Wiesje M. van der Flier and Sietske A.M. Sikkes Abstract: Objective:The Amsterdam Instrumental Activities of Daily…

  • Journal Cerebral Circulation – Cognition and Behavior

    Journal Cerebral Circulation – Cognition and Behavior

    “Validation of the brain health index in the European Prevention of Alzheimer’s Dementia cohort”

    Authors: Jodi K. Watt, David Alexander Dickie, Frederick K. Ho, Donald M. Lyall, Jesse Dawson, Terence J. Quinn, European Prevention of Alzheimer’s Disease (EPAD) Consortium

    Abstract:

    Background: Brain Health Index (BHI) assimilates various MRI sequences, giving a quantitative measure of brain health. To date, BHI validation has been cross-sectional and limited to selected populations. Further large-scale validation and assessment of temporal change is required to understand its clinical utility.

    Aim: Assess 1) relationships between variables associated with cognitive decline and BHI 2) associations between BHI and measures of cognition and 3) longitudinal changes in BHI and relationship with cognitive function.

    Methods: BHI computation involved Gaussian mixture-model cluster analysis of T1, T2, T2*, and T2 FLAIR MRI data from participants within the European Prevention of Alzheimer’s Dementia (EPAD) cohort. Group differences (gender- and health-based) were evaluated using independent samples Welch’s t-tests. Relationships between BHI, age and cognitive tests used linear regression. Longitudinal analysis (12/24 months) utilised mixed linear regression models to examine BHI changes, and paired BHI/cognition associations.

    Results: Data from N = 1496 predominantly Caucasian participants (50–88 years old, 43.32% male) were used. BHI scores were lower in those with diabetes (p < 0.001, d = 0.419), hypertension (p < 0.001, d = 0.375), hypercholesterolemia (p < 0.001, d = 0.193) and stroke (p < 0.05, d = 0.512). APOE was not significantly related to BHI scores. After correction for age, cross-sectional BHI scores were significantly associated with all measures of cognitive function in males, but only the Four Mountains Test (4MT) in females. Longitudinal change in BHI and cognition were not consistently related.

    Conclusions: BHI is a valid marker of cognitive decline and relatively stable over 1-2 year follow-up periods. Further work should assess temporal changes over a longer duration and determine relationships between BHI and cognition in more diverse populations.

    DOI: https://doi.org/10.1016/j.cccb.2024.100214

    Published online: 5 April 2024 in the Journal Cerebral Circulation – Cognition and Behavior

    by

    in

    “Validation of the brain health index in the European Prevention of Alzheimer’s Dementia cohort” Authors: Jodi K. Watt, David Alexander Dickie, Frederick K. Ho, Donald M. Lyall, Jesse Dawson, Terence J. Quinn, European Prevention of Alzheimer’s Disease (EPAD) Consortium Abstract: Background: Brain Health Index (BHI) assimilates various MRI sequences, giving a quantitative measure of brain…

  • Frontiers in Aging Neuroscience

    Frontiers in Aging Neuroscience

    “Modifiable dementia risk factors and AT(N) biomarkers: findings from the EPAD cohort”

    Authors: Eddy Roccati, Aidan David Bindoff, Jessica Marie Collins, Joshua Eastgate, Jay Borchard, Jane Alty, Anna Elizabeth King, James Clement Vickers, Margherita Carboni, Chad Logan, EPAD Consortium

    Abstract:

    Introduction: Modifiable risk factors account for a substantial proportion of Alzheimer’s disease (AD) cases and we currently have a discrete AT(N) biomarker profile for AD biomarkers: amyloid (A), p-tau (T), and neurodegeneration (N). Here, we investigated how modifiable risk factors relate to the three hallmark AT(N) biomarkers of AD.

    Methods: Participants from the European Prevention of Alzheimer’s Dementia (EPAD) study underwent clinical assessments, brain magnetic resonance imaging, and cerebrospinal fluid collection and analysis. Generalized additive models (GAMs) with penalized regression splines were modeled in the AD Workbench on the NTKApp.

    Results: A total of 1,434 participants were included (56% women, 39% APOE ε4+) with an average age of 65.5 (± 7.2) years. We found that modifiable risk factors of less education (t = 3.9, p < 0.001), less exercise (t = 2.1, p = 0.034), traumatic brain injury (t = −2.1, p = 0.036), and higher body mass index (t = −4.5, p < 0.001) were all significantly associated with higher AD biomarker burden.

    Discussion: This cross-sectional study provides further support for modifiable risk factors displaying neuroprotective associations with the characteristic AT(N) biomarkers of AD.

    DOI: https://doi.org/10.3389/fnagi.2024.1346214

    Published online: 7 February 2024 in the Journal Frontiers in Aging Neuroscience

    by

    in

    “Modifiable dementia risk factors and AT(N) biomarkers: findings from the EPAD cohort” Authors: Eddy Roccati, Aidan David Bindoff, Jessica Marie Collins, Joshua Eastgate, Jay Borchard, Jane Alty, Anna Elizabeth King, James Clement Vickers, Margherita Carboni, Chad Logan, EPAD Consortium Abstract: Introduction: Modifiable risk factors account for a substantial proportion of Alzheimer’s disease (AD) cases and…

  • Frontiers in Neurology

    Frontiers in Neurology

    “The European Prevention of Alzheimer’s Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer’s disease dementia”

    Authors: Stina Saunders, Sarah Gregory, Matthew H S Clement, Cindy Birck, Serge van der Geyten, Craig W Ritchie

    Abstract:

    Introduction: Tens of millions of people worldwide will develop Alzheimer’s disease (AD), and only by intervening early in the preclinical disease can we make a fundamental difference to the rates of late-stage disease where clinical symptoms and societal burden manifest. However, collectively utilizing data, samples, and knowledge amassed by large-scale projects such as the Innovative Medicines Initiative (IMI)-funded European Prevention of Alzheimer’s Dementia (EPAD) program will enable the research community to learn, adapt, and implement change.

    Method: In the current article, we define and discuss the substantial assets of the EPAD project for the scientific community, patient population, and industry, describe the EPAD structure with a focus on how the public and private sector interacted and collaborated within the project, reflect how IMI specifically supported the achievements of the above, and conclude with a view for future.

    Results: The EPAD project was a €64-million investment to facilitate secondary prevention of AD dementia research. The project recruited over 2,000 research participants into the EPAD longitudinal cohort study (LCS) and included over 400 researchers from 39 partners. The EPAD LCS data and biobank are freely available and easily accessible via the Alzheimer’s Disease Data Initiative’s (ADDI) AD Workbench platform and the University of Edinburgh’s Sample Access Committee. The trial delivery network established within the EPAD program is being incorporated into the truly global offering from the Global Alzheimer’s Platform (GAP) for trial delivery, and the almost 100 early-career researchers who were part of the EPAD Academy will take forward their experience and learning from EPAD to the next stage of their careers.

    Discussion: Through GAP, IMI-Neuronet, and follow-on funding from the Alzheimer’s Association for the data and sample access systems, the EPAD assets will be maintained and, as and when sponsors seek a new platform trial to be established, the learnings from EPAD will ensure that this can be developed to be even more successful than this first pan-European attempt.

    DOI: 10.3389/fneur.2022.1051543

    Published online: 22 November 2022 in the Journal Frontiers in Neurology

    by

    in

    “The European Prevention of Alzheimer’s Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer’s disease dementia” Authors: Stina Saunders, Sarah Gregory, Matthew H S Clement, Cindy Birck, Serge van der Geyten, Craig W Ritchie Abstract: Introduction: Tens of millions of people worldwide will develop Alzheimer’s disease (AD), and only by intervening early in the preclinical disease…

  • Neurobiology of Aging

    Neurobiology of Aging

    “Spatial cognition is associated with levels of phosphorylated-tau and β-amyloid in clinically normal older adults”

    Authors: Gillian Coughlan, Brennan DeSouza, Peter Zhukovsky, Michael Hornberger, Cheryl Grady, Rachel F Buckley; European Prevention of Alzheimer’s Disease (EPAD) Consortium

    Abstract:

    Spatial cognition is associated with Alzheimer’s disease (AD) biomarkers in the symptomatic stages of the disease. We investigated whether cerebrospinal fluid (CSF) biomarkers (phosphorylated-tau [p-tau] and β-amyloid) are associated with poorer spatial cognition in clinically normal older adults. Participants were 1875 clinically normal adults (age 67.8 [8.5] years) from the European Prevention of Alzheimer’s Dementia Consortium. Mixed effect models assessed the cross-sectional association between p-tau181, β-amyloid1-42 (Aβ1-42) and p-tau181/Aβ1-42 ratio and spatial cognition measured using semi-automated Supermarket Task and the 4 Mountains Task. Levels of p-tau181, Aβ1-42, and p-tau181/Aβ1-42 ratio were significantly associated with spatial cognition scores on both tasks. The p-tau181/Aβ1-42 ratio showed the largest effect sizes (β = -0.04/0.05, p < 0.001). Lower entorhinal cortical volume was associated with poorer outcomes on both tasks (β = 0.06, p < 0.002) and accounted for 18%-22% of the direct association between p-tau181 and spatial cognition scores. In conclusion, degeneration of the entorhinal cortex mediates a significant proportion of the association between p-tau181 and spatial assessments in cognitively normal adults. Future studies should focus on increasing the sensitivity of digital spatial assessments.

    DOI: 10.1016/j.neurobiolaging.2023.06.016

    Published online: 29 June 2023 in the Journal Neurobiology of Aging

    by

    in

    “Spatial cognition is associated with levels of phosphorylated-tau and β-amyloid in clinically normal older adults” Authors: Gillian Coughlan, Brennan DeSouza, Peter Zhukovsky, Michael Hornberger, Cheryl Grady, Rachel F Buckley; European Prevention of Alzheimer’s Disease (EPAD) Consortium Abstract: Spatial cognition is associated with Alzheimer’s disease (AD) biomarkers in the symptomatic stages of the disease. We investigated whether cerebrospinal fluid (CSF) biomarkers (phosphorylated-tau…

  • Alzheimer’s & Dementia

    Alzheimer’s & Dementia

    “Precision prevention of Alzheimer’s and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies”

    Authors: Giovanni B Frisoni, José Luis Molinuevo, Daniele Altomare, Emmanuel Carrera, Frederik Barkhof, Johannes Berkhof, Julien Delrieu, Bruno Dubois, Miia Kivipelto, Agneta Nordberg, Jonathan M Schott, Wiesje M van der Flier, Bruno Vellas Frank Jessen, Philip Scheltens, Craig Ritchie

    Abstract:

    Empirical evidence suggests that a fair proportion of dementia cases are preventable, that some preventive actions can be taken immediately, and others may soon be implemented. Primary prevention may target cognitively normal persons with modifiable risk factors through lifestyle and multiple domain interventions (including general cardiovascular health). While the effect on individuals may be modest, it might have a large societal impact by decreasing overall dementia incidence by up to 35%. Secondary prevention will target cognitively normal persons at high risk of dementia due to Alzheimer’s disease pathology with future anti-amyloid, anti-tau, or other drugs. This approach is likely to have major benefits to both individuals and society. Memory clinics will need structural and functional changes to adapt to novel technologies and increased patients’ demands, and brand-new services may need to be developed with specific skills on risk profiling, risk communication, and personalized risk reduction plans.

    DOI: 10.1002/alz.12132

    Published online: 16 October 2020 in the Journal Alzheimer’s & Dementia

    by

    in

    “Precision prevention of Alzheimer’s and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies” Authors: Giovanni B Frisoni, José Luis Molinuevo, Daniele Altomare, Emmanuel Carrera, Frederik Barkhof, Johannes Berkhof, Julien Delrieu, Bruno Dubois, Miia Kivipelto, Agneta Nordberg, Jonathan M Schott, Wiesje M van der Flier, Bruno Vellas Frank Jessen, Philip Scheltens, Craig Ritchie Abstract: Empirical evidence suggests that a fair proportion of…

  • Annals of Clinical and Translational Neurology

    Annals of Clinical and Translational Neurology

    “Alzheimer’s Disease and Small Vessel Disease Differentially Affect White Matter Microstructure”

    Authors: Mario Tranfa, Luigi Lorenzini, Lyduine E. Collij, David Vállez García, Silvia Ingala, Giuseppe Pontillo, Leonard Pieperhoff, Alessio Maranzano, Robin Wolz, Sven Haller, Kaj Blennow, Giovanni Frisoni, Carole H. Sudre, Gael Chételat, Michael Ewers, Pierre Payoux, Adam Waldman, Pablo Martinez-Lage, Adam J. Schwarz, Craig W. Ritchie, Joanna M. Wardlaw, Juan Domingo Gispert, Arturo Brunetti, Henk J. M. M. Mutsaerts, Alle Meije Wink, Frederik Barkhof

    Abstract:

    Objective: Alzheimer’s disease (AD) and cerebral small vessel disease (cSVD), the two most common causes of dementia, are characterized by white matter (WM) alterations diverging from the physiological changes occurring in healthy aging. Diffusion tensor imaging (DTI) is a valuable tool to quantify WM integrity non-invasively and identify the determinants of such alterations. Here, we investigated main effects and interactions of AD pathology, APOE-ε4, cSVD, and cardiovascular risk on spatial patterns of WM alterations in non-demented older adults.

    Methods: Within the prospective European Prevention of Alzheimer’s Dementia study, we selected 606 participants (64.9 ± 7.2 years, 376 females) with baseline cerebrospinal fluid samples of amyloid β1-42 and p-Tau181 and MRI scans, including DTI scans. Longitudinal scans (mean follow-up time = 1.3 ± 0.5 years) were obtained in a subset (n = 223). WM integrity was assessed by extracting fractional anisotropy and mean diffusivity in relevant tracts. To identify the determinants of WM disruption, we performed a multimodel inference to identify the best linear mixed-effects model for each tract.

    Results: AD pathology, APOE-ε4, cSVD burden, and cardiovascular risk were all associated with WM integrity within several tracts. While limbic tracts were mainly impacted by AD pathology and APOE-ε4, commissural, associative, and projection tract integrity was more related to cSVD burden and cardiovascular risk. AD pathology and cSVD did not show any significant interaction effect.

    Interpretation: Our results suggest that AD pathology and cSVD exert independent and spatially different effects on WM microstructure, supporting the role of DTI in disease monitoring and suggesting independent targets for preventive medicine approaches.

    DOI: doi.org/10.1002/acn3.52071

    Published online: 16 May 2024 in the Journal Annals of Clinical and Translational Neurology

    by

    in

    “Alzheimer’s Disease and Small Vessel Disease Differentially Affect White Matter Microstructure” Authors: Mario Tranfa, Luigi Lorenzini, Lyduine E. Collij, David Vállez García, Silvia Ingala, Giuseppe Pontillo, Leonard Pieperhoff, Alessio Maranzano, Robin Wolz, Sven Haller, Kaj Blennow, Giovanni Frisoni, Carole H. Sudre, Gael Chételat, Michael Ewers, Pierre Payoux, Adam Waldman, Pablo Martinez-Lage, Adam J. Schwarz, Craig W. Ritchie, Joanna M. Wardlaw, Juan Domingo Gispert, Arturo Brunetti, Henk J. M. M. Mutsaerts, Alle Meije Wink, Frederik Barkhof Abstract: Objective: Alzheimer’s disease (AD)…